Press Release
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA
15 Nov, 2021
81
3599
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
12 Nov, 2021
82
3596
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH
08 Nov, 2021
99
3590
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China
19 Oct, 2021
103
3579
BIOGEN AND INNOCARE ANNOUNCE DOSING OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL OF ORELABRUTINIB FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN CHINA
14 Oct, 2021
84
3612
Mantle Cell Lymphoma Clinical Trail Sites in U.S.
01 Oct, 2021
109
3571
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355
16 Sep, 2021
131
3545
InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723
31 Aug, 2021
114
3522